NCT05131984View on ClinicalTrials.gov

Ocrelizumab Access by Socio-Economic Status

UnknownOBSERVATIONAL
Enrollment

600

Participants

Timeline

Start Date

November 15, 2021

Primary Completion Date

July 1, 2022

Study Completion Date

October 1, 2022

Conditions
Multiple Sclerosis
Interventions
DRUG

Ocrelizumab

At least 3 treatments (two loading treatments of 300mg each, and one full dose treatment of 600 mg over the course of 1 year

Trial Locations (1)

02115

Brigham and Women's Hospital, Boston

Sponsors
All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

collaborator

Boston Medical Center

OTHER

lead

Brigham and Women's Hospital

OTHER